| |
 |
ARTICLES 
|
|
| Is chemotherapy for metastatic non-small cell lung cancer "worth it"? |
| JC Ruckdeschel |
|
JCO Aug 1 1990: 1293–1296.
[PDF]
|
 |
| Small differences, big implications |
| IC Henderson |
|
JCO Aug 1 1990: 1297–1300.
[PDF]
|
|
|
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer |
| |
L Jaakkimainen, PJ Goodwin, J Pater, P Warde, N Murray, and E Rapp |
| |
JCO Aug 1 1990: 1301–1309.
[Abstract]
[PDF]
|
|
|
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo- Hormone Therapy Cooperative Group |
| |
F Boccardo, A Rubagotti, P Bruzzi, M Cappellini, G Isola, I Nenci, A Piffanelli, A Scanni, P Sismondi, and L Santi |
| |
JCO Aug 1 1990: 1310–1320.
[Abstract]
[PDF]
|
|
|
3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer |
| |
R Silvestrini, MG Daidone, P Valagussa, G Di Fronzo, G Mezzanotte, L Mariani, and G Bonadonna |
| |
JCO Aug 1 1990: 1321–1326.
[Abstract]
[PDF]
|
|
|
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer |
| |
JK Camoriano, CL Loprinzi, JN Ingle, TM Therneau, JE Krook, and MH Veeder |
| |
JCO Aug 1 1990: 1327–1334.
[Abstract]
[PDF]
|
|
|
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy |
| |
JL Speyer, U Beller, N Colombo, J Sorich, JC Wernz, H Hochster, M Green, R Porges, FM Muggia, and R Canetta |
| |
JCO Aug 1 1990: 1335–1341.
[Abstract]
[PDF]
|
|
|
Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study |
| |
M al-Sarraf, TF Pajak, JS Cooper, M Mohiuddin, A Herskovic, and PJ Ager |
| |
JCO Aug 1 1990: 1342–1351.
[Abstract]
[PDF]
|
|
|
Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy |
| |
DP Kelsen, B Minsky, M Smith, J Beitler, D Niedzwiecki, D Chapman, M Bains, M Burt, R Heelan, and B Hilaris |
| |
JCO Aug 1 1990: 1352–1361.
[Abstract]
[PDF]
|
|
|
A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group |
| |
RC Coombes, PS Schein, CE Chilvers, J Wils, G Beretta, JM Bliss, A Rutten, D Amadori, H Cortes-Funes, and A Villar-Grimalt |
| |
JCO Aug 1 1990: 1362–1369.
[Abstract]
[PDF]
|
|
|
Large-cell lymphomas: clinical and prognostic features |
| |
RS Stein, JP Greer, JM Flexner, JD Hainsworth, RD Collins, WR Macon, and JB Cousar |
| |
JCO Aug 1 1990: 1370–1379.
[Abstract]
[PDF]
|
|
|
Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19) |
| |
SC Raimondi, FG Behm, PK Roberson, DL Williams, CH Pui, WM Crist, AT Look, and GK Rivera |
| |
JCO Aug 1 1990: 1380–1388.
[Abstract]
[PDF]
|
|
|
Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study |
| |
MJ Borowitz, JJ Shuster, CI Civin, AJ Carroll, AT Look, FG Behm, VJ Land, DJ Pullen, and WM Crist |
| |
JCO Aug 1 1990: 1389–1398.
[Abstract]
[PDF]
|
|
|
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors |
| |
CB Pratt, MP Goren, WH Meyer, B Singh, and RK Dodge |
| |
JCO Aug 1 1990: 1399–1401.
[Abstract]
[PDF]
|
|
|
Sex-associated differences in presentation and survival in patients with lung cancer |
| |
MK Ferguson, C Skosey, PC Hoffman, and HM Golomb |
| |
JCO Aug 1 1990: 1402–1407.
[Abstract]
[PDF]
|
|
|
Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma |
| |
KA Jaeckle, A Mittelman, and FH Hill |
| |
JCO Aug 1 1990: 1408–1418.
[Abstract]
[PDF]
|
|
|
Chemotherapy of invasive thymoma |
| |
A Fornasiero, O Daniele, C Ghiotto, F Sartori, F Rea, M Piazza, L Fiore-Donati, P Morandi, SM Aversa, and A Paccagnella |
| |
JCO Aug 1 1990: 1419–1423.
[Abstract]
[PDF]
|
|
|
The myelodysplastic syndromes: biology and implications for management |
| |
AF List, HS Garewal, and AA Sandberg |
| |
JCO Aug 1 1990: 1424–1441.
[Abstract]
[PDF]
|
|
| Contribution of mercaptopurine dose intensification to improved outcome in patients with lower-risk ALL |
| M Abromowitch and D Fairclough |
|
JCO Aug 1 1990: 1442–1443.
[PDF]
|
|
| Partial remission and resectability |
| MH Cohen |
|
JCO Aug 1 1990: 1443–1444.
[PDF]
|
|
| Interferons in the treatment of multiple myeloma |
| DE Bergsagel, P von Wussow, R Alexanian, G Avvisati, R Bataille, B Barlogie, E Borden, F Caligaris-Cappio, H Deicher, and BG Durie |
|
JCO Aug 1 1990: 1444–1445.
[PDF]
|
|
| The forgotten group at risk for breast cancer |
| VC Jordan |
|
JCO Aug 1 1990: 1445–1446.
[PDF]
|
|
